OCRA Invests Record $9.2 Million in Research Initiatives for 2024

Research breakthroughs are around the corner. In 2023, OCRA announced $9.2 million in research initiatives for 2024 — the largest in our history — including awarding 20 grants to scientists at 15 prestigious institutions.

Recommended for funding by OCRA’s Scientific Advisory Committee from a competitive evaluation process, these exceptional researchers and their forward-thinking studies will tackle some of the most pressing challenges faced by the ovarian and gynecologic cancer community:

  • Harnessing AI to predict precision medicine’s impact
  • Improving health equity
  • Investigating chemotherapy resistance
  • Pursuing more effective immunotherapy
  • Preventing recurrence and metastasis
  • Identifying new biomarkers, and more

“At OCRA, we’re proud to invest in cutting-edge scientific investigation that has the potential to truly impact the course of ovarian and gynecologic cancer research,” said Dr. Ronald Alvarez, Chair of OCRA’s Scientific Advisory Committee. “Each of these grants has undergone an in-depth review by our Scientific Advisory Committee, a team of high-level experts in the field. We are extremely excited about the promise that they hold.”

As the largest private funder of ovarian cancer research, OCRA is tremendously grateful to the researchers undertaking efforts to defeat this disease and to our community whose support enabled this groundbreaking investment toward a better future.

Stay tuned for more details on our 2024 grantees and their studies poised to make progress against ovarian and related gynecologic cancers.

Supporters like you directly enabled this record investment in research. Enable more discoveries by donating today.

Posted on in OCRA News, Research